Shanghai Shyndec subsidiary secures new drug registration for 300mg Quetiapine Fumarate

Shanghai Shyndec Pharmaceutical announced that its wholly-owned subsidiary, Sinopharm Industrial Co., Ltd. (Sinopharm Industrial), has received a drug registration certificate for Quetiapine Fumarate Extended-Release Tablets (300mg) from the National Medical Products Administration. This follows a previous registration for the 200mg specification obtained on April 15, 2025.

The newly approved drug is a Class 4 chemical drug, indicated for the treatment of schizophrenia and bipolar disorder. According to an internal database, nationwide public medical institution sales of Quetiapine Fumarate Extended-Release Tablets in 2024 were approximately yuan 44,249 million.

Sinopharm Industrial's cumulative research and development investment for the 300mg Quetiapine Fumarate Extended-Release Tablets is approximately yuan 1,040.70 million (unaudited). The company notes that this additional specification will enrich its product portfolio, enhancing future market expansion and sales.